drugset / Trial / NCT04591275
Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .
RandomizedParallel-groupQuadruple-blindTreatment
Summary
evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)
Timeline
- Start
- 2021-03-31
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMAB807 | Monoclonal antibody | 60 mg | Subcutaneous |
| Comparator | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |